Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol

Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol

Background A prolonged release combined oral contraceptive (COC) pill, containing 2 mg dienogest (DNG)/0.02 mg ethinylestradiol (EE) in a 24 + 4 daily dosing regimen has recently been approved in Europe.Objective To determine if this COC impacts coagulation and fibrinolytic factors in comparison to...

Full description

Saved in:
Bibliographic Details
Main Authors: Pedro-Antonio Regidor, Alicyoy Angulo, Enrico Colli
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Gynecological Endocrinology
Subjects:
Coagulation
fibrinolysis
combined oral contraceptive
dienogest
prolonged release
Online Access:https://www.tandfonline.com/doi/10.1080/09513590.2025.2458708
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09513590.2025.2458708

Similar Items